

13/01/2010



***National Institute for
Health and Clinical Excellence***

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

www.nice.org.uk

Dear consultees and commentators,

Please find attached a document that describes NICE's Guidance Executive's conclusions after having received the final appraisal determination for the single technology appraisal of lapatinib for the treatment of advanced or metastatic breast cancer.

We have planned for this reconsideration to be held at the Committee meeting on 16 February 2010. You will not be asked to make further submissions.

This information is confidential until it is publicised on the website in 5 working days.

Yours truly,
Meindert Boysen
Programme Director Technology Appraisals